| abstract |
The present invention relates to an anti-CSF-1R antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. Further, the present invention relates to a chimeric antibody, a humanized antibody comprising a CDR region of the anti-CSF-1R antibody, and a pharmaceutical composition comprising the human anti-CSF-1R antibody and the antigen-binding fragment thereof, and the use thereof as an anticancer drug. In particular, the invention relates to the use of a humanized anti-CSF-1R antibody for the manufacture of a medicament for the treatment of a CSF-1R mediated disease or disorder. |